Free Newsletter
AstraZeneca launches $790M in Euro bonds
AstraZeneca is issuing more bonds to pay off its MedImmune debts. This time, it's an 18-month European issue to the tune of about $790 million; the bonds will be sold to institutions outside the U.S. and trade on the London exchange. The proceeds will cancel U.S. commercial paper the drugmaker took on to finance its buyout of the big biotech firm.
You'll recall that last fall AstraZeneca loosed a whopping $6.9 billion in bonds on the market, also to be used to pay off the MedImmune deal. The bond issue was a big success for the drugmaker, oversubscribed in all tranches.
- see the story at iStock Analyst
Related Articles:
AstraZeneca floats $6.9 billion in bonds
AstraZeneca snares MedImmune in $15.6B buyout
MedImmune CEO talks about AZ buyout
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: